CLINICAL & PIPELINE·Drug Approval
Lupin Secures Labeling Approval for Generic Contraceptive VYFEMLA Amidst Ongoing Quality Scrutiny
Lupin Pharmaceuticals secured supplemental labeling approval for its generic oral contraceptive, VYFEMLA (NORETHINDRONE AND ETHINYL ESTRADIOL), on April 29, 2022. This regulatory update ensures continued market access for the AB-rated product. However, procurement and supply chain leaders must consider Lupin's 'watch' risk band and history of quality recalls, necessitating enhanced supplier due diligence and diversified sourcing strategies for critical generic molecules.
90-Day Activity